uniQure Stock Price Target Raised on Blockbuster Opportunity
uniQure N.V. (NASDAQ: QURE) has seen its stock price target significantly increased by Wells Fargo, signaling strong confidence in the biotechnology company’s gene therapy programs and potential for future growth. The upward revision reflects positive sentiment surrounding uniQure’s lead candidate, AMT-130, and its potential to address a significant unmet medical need.
The stock closed at $54.99 yesterda, experiencing a 5.79% decrease from the previous day’s trading, and has moved flat on today’s session after testing $57. Despite this short-term dip, the broader market sentiment surrounding uniQure remains optimistic, fueled by analyst upgrades and promising clinical data. The current price reflects a degree of investor caution, but…
